The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 55.50
Bid: 53.00
Ask: 58.00
Change: 0.00 (0.00%)
Spread: 5.00 (9.434%)
Open: 55.50
High: 55.50
Low: 55.50
Prev. Close: 55.50
MYX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results of Fundraising

28 Feb 2019 16:54

RNS Number : 4975R
MyCelx Technologies Corporation
28 February 2019
 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATIONS (EU) NO. 596/2014. UPON THE PUBLICATION OF THIS ANNOUNCEMENT (THE "ANNOUNCEMENT") VIA A REGULATORY INFORMATION SERVICE ("RIS"), THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO ANY US PERSONS OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA.

 

MYCELX Technologies Corporation

("MYCELX" or the "Company")

 

Results of Fundraising

 

MYCELX Technologies Corporation (MYX LN), the clean water technology company providing patented solutions for the Oil and Gas market and commercial industrial markets worldwide traded on London Stock Exchange's AIM market, is pleased to announce the result of the Placing and Subscription announced earlier today.

 

A total of 577,246 New Common Shares in the Company have been placed by Cantor Fitzgerald Europe at a price of 230 pence per share (the "Issue Price") raising gross proceeds of $1.75 million. Together with the proceeds of the Subscription for 26,387 New Common Shares at the Issue Price raising gross proceeds of $80,000, the Company has raised a total of $1.83 million to fund its expansion.

 

The Issue Price represents a discount of 6.1 per cent. to the Company's mid-market closing price as at 27 February 2019, being the last practicable date prior to the publication of the announcement of the Fundraising.

 

Admission and Total Voting Rights

 

Application has been made to the London Stock Exchange for the New Common Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission will become effective at 08.00 a.m. on 13 March 2019.

 

Upon Admission, the New Common Shares will trade in the Company's new restricted line of Common Shares under the ticker MYXR, and the New Common Shares, as represented by Depositary Interests, will be held in the CREST system and will be segregated into a separate trading system within CREST identified with the market "REG S" and ISIN USU624551151. The Company also maintains an unrestricted line of Common Shares trading under the existing symbol MYX.

 

Following the issue of the 603,633 New Common Shares, the Company's issued share capital will comprise 19,411,250 Common Shares. The total number of voting rights in the company will be 19,411,250. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.

 

Related party transactions

 

City Financial Investment Company Limited and Canaccord Genuity Wealth Limited are substantial shareholders of the Company (the "Substantial Shareholders") and therefore classified as related parties under the AIM Rules for Companies ("AIM Rules"). Tim Eggar, Connie Mixon and Andre Schnabl (the "Participating Directors") are, by virtue of their directorships of the Company, also related parties of the Company under the AIM Rules. The Substantial Shareholders and Participating Directors (together the "Related Parties") are participating in the Fundraising and their participation in the Fundraising is considered a related party transaction under the AIM Rules.

 

The independent directors of the Company, having consulted with the Company's nominated adviser, Cantor Fitzgerald Europe, consider that the terms of the Related Parties' participation in the Fundraising is fair and reasonable insofar as the Company's Shareholders are concerned.

 

The Related Parties' interest in the Company, following Admission, will be:

 

Related Party

Current Shareholding

Shares being acquired pursuant to the Fundraising

Shareholding following Admission

Percentage holding following Admission

City Financial Investments Company Limited

3,574,938

82,463

3,657,401

18.84%

Canaccord Genuity Wealth Limited

2,639,507

494,783

3,134,290

16.15%

Andre Schnabl

-

8,246

8,246

0.04%

Connie Mixon

991,211

16,492

1,007,703

5.19%

Tim Eggar

130,680

1,649

132,329

0.68%

 

 

 

Connie Mixon, CEO of MYCELX, said:

 

"I am pleased to announce the successful closing of this capital raise that will fund the purchase of additional revenue-generating assets for MYCELX. The Company has a strong track record of project delivery and we achieved significant growth in 2018. The purchase of these assets will enable us to accelerate and exploit the opportunities we see before us, as we continue to convert our pipeline into purchase orders and build on the strong momentum we have achieved to date globally."

 

 

All capitalised terms in this announcement are as defined in the Company's announcement released at 07.00 a.m. this morning.

 

For further information, please contact:

 

MYCELX Technologies Corporation

Connie Mixon, Chief Executive Officer

+1 770 534 3118

Kim Slayton, Chief Financial Officer

Cantor Fitzgerald Europe (NOMAD, Broker and Bookrunner)

David Porter

Richard Salmond

+44 207 894 7000

Celicourt Communications

Mark Antelme

+44 20 7520 9266

Jimmy Lea

 

 

About MYCELX

 

MYCELX is a revolutionary oil-free water technology company solving the world's toughest oil removal problems in the oil and gas industry. The systems are based upon scientific breakthrough for a completely different approach to permanent oil removal. The Company created the patented MYCELX polymer using innovative molecular cohesion for removing oil from water far beyond what conventional systems have ever achieved. MYCELX systems remove oil to critically low levels in a much smaller physical footprint than conventional systems. Learn more about the Company by visiting https://www.MYCELX.com/. 

 

 

Appendix - PDMR Dealing Disclosure:

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Connie Mixon

2.

Reason for the Notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MYCELX Technologies Corporation

b)

LEI

213800UJZINIK2VD1G48

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Common shares of $0.025 each

Identification code

USU624551151

b)

Nature of the transaction

Purchase of shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

230 pence

16,492 (bought)

d)

Aggregated information:

· Aggregated volume

· Price

16,492 common shares of $0.025 each ("Common Shares") at an average price of 230 pence per share

e)

Date of the transaction

28 February 2019

f)

Place of the transaction

Outside a trading venue

 

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Tim Eggar

2.

Reason for the Notification

a)

Position/status

Non-Executive Chairman

b)

Initial notification/Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MYCELX Technologies Corporation

b)

LEI

213800UJZINIK2VD1G48

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Common shares of $0.025 each

Identification code

USU624551151

b)

Nature of the transaction

Purchase of shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

230 pence

1,649 (bought)

d)

Aggregated information:

· Aggregated volume

· Price

1,649 common shares of $0.025 each ("Common Shares") at an average price of 230 pence per share

e)

Date of the transaction

28 February 2019

f)

Place of the transaction

Outside a trading venue

 

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Andre Schnabl

2.

Reason for the Notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MYCELX Technologies Corporation

b)

LEI

213800UJZINIK2VD1G48

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Common shares of $0.025 each

Identification code

USU624551151

b)

Nature of the transaction

Purchase of shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

230 pence

8,246 (bought)

d)

Aggregated information:

· Aggregated volume

· Price

8,246 common shares of $0.025 each ("Common Shares") at an average price of 230 pence per share

e)

Date of the transaction

28 February 2019

f)

Place of the transaction

Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
STRTPMFTMBATBML
Date   Source Headline
14th Oct 20217:00 amRNSMiddle East Contract Win
29th Sep 20217:00 amRNSHalf Year Results Statement
31st Aug 20217:00 amRNSNotice of Interim Results & Investor Presentation
11th Aug 20217:00 amRNSHolding(s) in Company
4th Aug 20217:00 amRNSContract Award and Contract Extension
7th Jul 20215:41 pmRNSResult of AGM
4th Jun 20218:00 amRNSMailing of Annual Financial Report and AM Notice
26th May 20217:00 amRNSFinal Results for the year ending 31 December 2020
19th May 20217:00 amRNSInvestor Presentation
14th May 20217:00 amRNSPFAS System Validation
13th Apr 20211:49 pmRNSGrant of Options
23rd Mar 20217:00 amRNSBoard Changes
17th Mar 20213:37 pmRNSHolding(s) in Company
17th Mar 20212:35 pmRNSHolding(s) in Company
15th Mar 20217:00 amRNSHolding(s) in Company
2nd Mar 20217:00 amRNSTrading Update
18th Feb 20217:00 amRNSSale of MYCELX property in Duluth, USA
17th Feb 20214:32 pmRNSHolding(s) in Company
5th Jan 20212:32 pmRNSHolding(s) in Company
4th Jan 20217:00 amRNSHolding(s) in Company
27th Oct 20202:55 pmRNSResult of Annual Meeting
2nd Oct 20202:56 pmRNSNotice of Annual Meeting
22nd Sep 20207:00 amRNSHalf Year Results Statement
4th Sep 20207:00 amRNSAppointment of Nominated Adviser and Sole Broker
7th Aug 202011:50 amRNSDirector/PDMR Shareholding
22nd Jun 20207:00 amRNSContract extension with SABIC
19th Jun 20207:00 amRNSAnnual Financial Report
27th May 20207:00 amRNSFinal Results for the year ending 31 December 2019
11th May 20207:00 amRNSNew Project Award
14th Apr 20207:00 amRNSTrading Update
9th Mar 20207:00 amRNSClosure of Restricted Stock Line
5th Mar 20207:00 amRNSTrading Update
13th Dec 201910:25 amRNSBlock listing Interim Review
4th Nov 20197:00 amRNSTrading Update
16th Sep 20197:00 amRNSHalf Year Results Statement
20th Aug 201912:42 pmRNSHolding(s) in Company
16th Aug 20193:02 pmRNSDirector Shareholding
29th Jul 20197:00 amRNSDirectorate Changes
26th Jul 20197:00 amRNSAppointment of Nominated Adviser & Broker
22nd Jul 20191:34 pmRNSHolding(s) in Company
10th Jul 201912:57 pmRNSResult of Annual Meeting
14th Jun 20197:00 amRNSTrading Update
11th Jun 20197:00 amRNSBlock listing Interim Review
6th Jun 20197:00 amRNSIssue of Equity
31st May 20191:57 pmRNSAnnual Financial Report
13th May 20197:00 amRNSFinal Results for the year ending 31 December 2018
28th Mar 20197:00 amRNSHolding(s) in Company
15th Mar 20197:00 amRNSHolding(s) in Company
15th Mar 20197:00 amRNSHolding(s) in Company
13th Mar 20197:00 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.